The stock of Cellceutix Corp (OTCMKTS:CTIX) nosedived by more than 8% during the last trading session, though there was no information or market update to send the shares down. The stock of the company settled at $2.52 as a total of 218,121 shares traded hands. The only recent update from the company came with respect to the addition of independent directors and committee members on its board. Last week, the company released a press note informing that Dr. Barry Alan Schechter, Dr. Zorik Spektor, and Mark Tobin has joined as independent directors on the board.
Brief profile of the directors
At the same time, Cellceutix Corp (OTCMKTS:CTIX) mentioned a brief profile of all the new joinees. As per which, Dr. Schechter is said to be serving Florida Eye Microsurgical Institute in the capacity of Director of Department of Cornea and External Disease. Dr. Schechter is associated with the said institute from last ten years. He has also co-founded Media vision, which aims to save the eyesight of children, the company noted in its statement.
Dr. Spektor is a M.D., F.A.A.P., who is a Head and Neck Surgeon alongside being a Pediatric Otolaryngologist. As per the records, Dr. Spektor has been working with the Center for Pediatric ENT- Head and Neck Surgery since the last 20 years.
Turning to Mr. Tobin, Cellceutix Corp (OTCMKTS:CTIX) noted that he is presently serving as Director in Digital Offering. He takes care of the Research department in his present assignment. Apart from which, Mr. Tobin has vast knowledge of finance as a result of his association with a merchant bank since 2013. Mr. Tobin is also a managing partner at Tobin Tao & Company, Cellceutix Corp (OTCMKTS:CTIX) briefed.
Additionally, the company said that the presentations delivered at the European Congress is made available on its website. While, Cellceutix Corp (OTCMKTS:CTIX) also updated the stakeholders with developments related to Briladicin.